SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on March 20, 2019. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and identifies as an Emerging Growth Company. Note: The request metadata referenced "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The report focuses solely on the announcement of an upcoming investor presentation.
Guidance, Outlook, and Management Commentary
On March 20, 2019, Cerecor Inc. presented at the Oppenheimer & Co. Inc. 29th Annual Healthcare Conference in New York. A slide show presentation from this event is attached as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Slide Show Presentation) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm the registrant name is Cerecor Inc., not Avalo Therapeutics, Inc.
- Note that the presentation materials are not legally "filed" with the SEC and carry different liability standards under Section 18 of the Exchange Act.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial metrics referenced in the presentation.